0001562180-23-001426.txt : 20230215
0001562180-23-001426.hdr.sgml : 20230215
20230215164719
ACCESSION NUMBER: 0001562180-23-001426
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20230213
FILED AS OF DATE: 20230215
DATE AS OF CHANGE: 20230215
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Gault Laura
CENTRAL INDEX KEY: 0001951944
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36544
FILM NUMBER: 23636024
MAIL ADDRESS:
STREET 1: C/O SAGE THERAPEUTICS, INC.
STREET 2: 245 FIRST STREET, SUITE 16
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sage Therapeutics, Inc.
CENTRAL INDEX KEY: 0001597553
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 215 FIRST STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-299-8380
MAIL ADDRESS:
STREET 1: 215 FIRST STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2023-02-13
false
0001597553
Sage Therapeutics, Inc.
SAGE
0001951944
Gault Laura
C/O SAGE THERAPEUTICS, INC
215 FIRST STREET
CAMBRIDGE
MA
02142
false
true
false
false
Chief Medical Officer
Stock Option (Right to Buy)
45.28
2023-02-13
4
A
false
2660.00
0.00
A
2033-02-13
Common Stock
2660.00
2660.00
D
The securities awarded on February 13, 2023 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. Options to purchase 665 shares of common stock shall vest on the one year anniversary of February 13, 2023, with 1,995 shares vesting in 36 equal monthly installments thereafter.
/s/ Jennifer Fitzpatrick, as Attorney-in-Fact for Laura Gault
2023-02-15
EX-24
2
lgaultpoa.txt
POWER OF ATTORNEY
POWER OF ATTORNEY
I, the undersigned, hereby authorize and designate Anne Marie
Cook (SVP, General Counsel), Kimi Iguchi (Chief Financial Officer)
and Jennifer Fitzpatrick (VP, Corporate Counsel), for as long as they
remain employees of Sage Therapeutics, Inc., and Stuart Falber of
WilmerHale, each acting singly, or their successors in role, to take
the following actions, acting as my agent and attorney-in-fact, with
full power of substitution:
(1) to prepare and sign on my behalf any Form 4 or Form 5
pursuant to Section 16 of the Securities Exchange Act of 1934, as
amended, and to file the same with the Securities and Exchange
Commission, Nasdaq, NYSE, and each stock exchange on which shares of
Common Stock or other securities of Sage Therapeutics, Inc. are
listed, as required by law;
(2) to prepare and sign on my behalf any Form 144 pursuant
to the Securities Act of 1933, as amended, and to file the same with
the Securities and Exchange Commission, Nasdaq, NYSE, and each stock
exchange on which shares of Common Stock or other securities of Sage
Therapeutics, Inc. are listed, as required by law; and
(3) take any other action necessary or proper in
connection with the foregoing.
Unless earlier revoked under the next sentence, this Power of
Attorney shall remain in effect as long as I am a director or
executive officer of Sage Therapeutics, Inc., and shall not be
affected by my subsequent disability or incompetence. I may revoke
this Power of Attorney by written notice delivered, in person or by
nationally recognized courier, to the attention of the SVP, General
Counsel of Sage Therapeutics, Inc.
/s/ Laura Gault
Name: Laura Gault
Date: November 1, 2022
P (617) 299-8380 . F (617) 299-8379 . 215 First Street, Cambridge, MA 02142